EUCTR2004-005054-31-IT进行中（未招募）不适用
A phase IV open-label study of predictive markers in Growth Hormone Deficient and Turner Syndrome pre-pubertal children treated with SAIZEN.
INDUSTRIA FARMACEUTICA SERONO0 个研究点目标入组 326 人开始时间: 2005年9月20日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 326
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
A phase IV open-label study of predictive markers in Growth Hormone Deficient and Turner Syndrome prepubertal children treated with SaizeEUCTR2004-005054-31-SEMerck Serono International S.A.326
进行中（未招募）
不适用
A phase IV open-label study of predictive markers in Growth Hormone Deficient and Turner Syndrome prepubertal children treated with Saize- growth failure in children caused by decreased or absent secretion of endogenous growth hormone.- growth failure in girls with gonadal dysgenesis (Turner Syndrome), confirmed by chromosomal analysis.MedDRA version: 7.1Level: PTClassification code 10056438EUCTR2004-005054-31-ATSerono International S.A.326
进行中（未招募）
1 期
A phase IV open-label study of predictive markers in Growth Hormone Deficient and Turner Syndrome prepubertal children treated with SAIZEN.Estudio abierto en fase IV sobre marcadores predictivos en niños prepuberales con Déficit de Hormona de Crecimiento y síndrome de Turner tratados con Saizen R. - Predictive markers in GHD and TS children treated with SAIZEN.EUCTR2004-005054-31-ESSerono International S.A.318
进行中（未招募）
不适用
A phase IV open-label study of predictive markers in Growth Hormone Deficient and Turner Syndrome prepubertal children treated with Saize- growth failure in children caused by decreased or absent secretion of endogenous growth hormone.- growth failure in girls with gonadal dysgenesis (Turner Syndrome), confirmed by chromosomal analysis.MedDRA version: 7.1Level: PTClassification code 10056438EUCTR2004-005054-31-DEMerck Serono International S.A.326
进行中（未招募）
不适用
A phase IV open-label study of predictive markers in Growth Hormone Deficient and Turner Syndrome prepubertal children treated with Saize- growth failure in children caused by decreased or absent secretion of endogenous growth hormone.- growth failure in girls with gonadal dysgenesis (Turner Syndrome), confirmed by chromosomal analysis.MedDRA version: 7.1Level: PTClassification code 10056438EUCTR2004-005054-31-FISerono International S.A.326